New drug combo aims to stall advanced breast cancer in High-Risk patients
NCT ID NCT04208178
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 34 times
Summary
This study tests whether adding the drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). About 19 participants who have already received initial chemotherapy will receive either alpelisib or a placebo alongside their regular treatment. The goal is to see if the combination extends the time before the cancer worsens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HER2+BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Liège, 4000, Belgium
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Saint-Cloud, Hauts De Seine, 92210, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
University of California LA
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.